NO20022525L - Farmasöytiske formuleringer inneholdende zolmitriptan - Google Patents

Farmasöytiske formuleringer inneholdende zolmitriptan

Info

Publication number
NO20022525L
NO20022525L NO20022525A NO20022525A NO20022525L NO 20022525 L NO20022525 L NO 20022525L NO 20022525 A NO20022525 A NO 20022525A NO 20022525 A NO20022525 A NO 20022525A NO 20022525 L NO20022525 L NO 20022525L
Authority
NO
Norway
Prior art keywords
pharmaceutical formulations
formulations containing
zolmitriptan
containing zolmitriptan
formulation
Prior art date
Application number
NO20022525A
Other languages
English (en)
Other versions
NO20022525D0 (no
NO322119B1 (no
Inventor
Alan Roy Dearn
Sarah Louise Williamson
Simon John Summers
Trevor John Coomber
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10865629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20022525(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20022525D0 publication Critical patent/NO20022525D0/no
Publication of NO20022525L publication Critical patent/NO20022525L/no
Publication of NO322119B1 publication Critical patent/NO322119B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20022525A 1999-12-03 2002-05-28 Farmasøytiske formuleringer inneholdende zolmitriptan for intranasal administrering NO322119B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9928578.5A GB9928578D0 (en) 1999-12-03 1999-12-03 Pharmaceutical formulations
PCT/GB2000/004528 WO2001039772A1 (en) 1999-12-03 2000-11-28 Pharmaceutical formulations containing zolmitriptan

Publications (3)

Publication Number Publication Date
NO20022525D0 NO20022525D0 (no) 2002-05-28
NO20022525L true NO20022525L (no) 2002-05-28
NO322119B1 NO322119B1 (no) 2006-08-14

Family

ID=10865629

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022525A NO322119B1 (no) 1999-12-03 2002-05-28 Farmasøytiske formuleringer inneholdende zolmitriptan for intranasal administrering

Country Status (28)

Country Link
US (2) US6750237B1 (no)
EP (1) EP1237551B1 (no)
JP (1) JP2003515559A (no)
KR (1) KR100670092B1 (no)
CN (1) CN1222287C (no)
AT (1) ATE291914T1 (no)
AU (1) AU778092B2 (no)
BR (1) BRPI0016138B8 (no)
CA (1) CA2392050C (no)
CZ (1) CZ301528B6 (no)
DE (1) DE60019162T2 (no)
EE (1) EE05305B1 (no)
ES (1) ES2236001T3 (no)
GB (2) GB9928578D0 (no)
HK (2) HK1048445B (no)
HU (1) HU229458B1 (no)
IL (2) IL149578A0 (no)
IS (1) IS2135B (no)
MX (1) MXPA02005319A (no)
NO (1) NO322119B1 (no)
NZ (1) NZ518862A (no)
PL (1) PL200679B1 (no)
PT (1) PT1237551E (no)
RU (1) RU2255736C2 (no)
SK (1) SK287228B6 (no)
UA (1) UA75059C2 (no)
WO (1) WO2001039772A1 (no)
ZA (1) ZA200203704B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465468B1 (en) 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
WO2005115360A2 (en) * 2004-05-11 2005-12-08 Becton, Dickinson And Company Formulations of anti-pain agents and methods of using the same
EP1750677B1 (en) * 2004-05-28 2017-02-01 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
EP1812428A2 (en) * 2004-11-19 2007-08-01 Teva Pharmaceutical Industries Ltd Zolmitriptan crystal forms
CN100341504C (zh) * 2004-12-01 2007-10-10 鲁南制药集团股份有限公司 佐米曲普坦速释制剂
US9757455B2 (en) * 2005-11-28 2017-09-12 Johnson & Johnson Consumer Inc. Oral therapeutic compound delivery system
US20100048609A1 (en) * 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
JP2010507585A (ja) * 2006-10-19 2010-03-11 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換インドール
KR101517415B1 (ko) * 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
RU2611376C2 (ru) 2010-10-15 2017-02-21 Контера Фарма Апс Фармацевтическая композиция для лечения, профилактики или облегчения двигательных расстройств и ее применение
JP6121734B2 (ja) * 2012-02-09 2017-04-26 久光製薬株式会社 マイクロニードル用ゾルミトリプタン含有コーティング組成物及びマイクロニードルデバイス
NZ700474A (en) 2012-04-18 2016-10-28 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
KR101624049B1 (ko) 2014-10-29 2016-05-24 연세대학교 산학협력단 사카린을 이용한 용해도를 증가시킨 약제학적 조성물
CN108135916B (zh) * 2015-06-19 2022-01-28 北京科辉智药生物科技有限责任公司 手性特异性含硼化合物及其在治疗癌症或淀粉样变性中的应用
WO2017122161A1 (en) 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
AU2017297718B2 (en) 2016-07-11 2023-06-08 Contera Pharma A/S Pulsatile drug delivery system for treating morning akinesia
WO2019126766A1 (en) * 2017-12-21 2019-06-27 Taiwan Liposome Co., Ltd. Sustained-release triptan compositions and method of use the same through subdermal route or the like
US20210322343A1 (en) 2020-04-15 2021-10-21 Farzana Shaheen Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9012672D0 (en) * 1990-06-07 1990-08-01 Wellcome Found Therapeutic heterocyclic compounds
PT97888B (pt) * 1990-06-07 1998-12-31 Zeneca Ltd Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem
GB9516145D0 (en) * 1995-08-07 1995-10-04 Wellcome Found Improved chemical synthesis
US6255502B1 (en) 1996-07-11 2001-07-03 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
GB2315673A (en) * 1996-08-01 1998-02-11 Merck & Co Inc Treatment of migraine
AU718967B2 (en) * 1997-02-05 2000-05-04 Jagotec Ag Medical aerosol formulations
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
EE05305B1 (et) 2010-06-15
HK1048445B (en) 2005-08-26
GB2373726B (en) 2004-10-20
KR100670092B1 (ko) 2007-01-17
HK1048442A1 (en) 2003-04-04
CN1222287C (zh) 2005-10-12
ZA200203704B (en) 2003-10-29
PL200679B1 (pl) 2009-01-30
IL149578A (en) 2008-04-13
MXPA02005319A (es) 2002-12-06
EE200200283A (et) 2003-06-16
CA2392050C (en) 2009-11-24
UA75059C2 (uk) 2006-03-15
ATE291914T1 (de) 2005-04-15
NZ518862A (en) 2004-02-27
BR0016138A (pt) 2002-08-06
US7220767B2 (en) 2007-05-22
JP2003515559A (ja) 2003-05-07
PT1237551E (pt) 2005-07-29
HK1048445A1 (en) 2003-04-04
RU2002117649A (ru) 2004-01-27
HK1053430A1 (en) 2003-10-24
DE60019162T2 (de) 2006-02-02
BR0016138B1 (pt) 2013-09-10
AU1715701A (en) 2001-06-12
CZ301528B6 (cs) 2010-04-07
RU2255736C2 (ru) 2005-07-10
HK1048442B (zh) 2005-05-13
IL149578A0 (en) 2002-11-10
HU229458B1 (en) 2013-12-30
WO2001039772A1 (en) 2001-06-07
IS6394A (is) 2002-05-24
SK7532002A3 (en) 2002-12-03
NO20022525D0 (no) 2002-05-28
HUP0203597A2 (hu) 2003-02-28
CZ20021901A3 (cs) 2002-11-13
US20040214899A1 (en) 2004-10-28
AU778092B2 (en) 2004-11-18
BRPI0016138B8 (pt) 2021-05-25
EP1237551A1 (en) 2002-09-11
CN1402636A (zh) 2003-03-12
EP1237551B1 (en) 2005-03-30
ES2236001T3 (es) 2005-07-16
GB2373726A (en) 2002-10-02
CA2392050A1 (en) 2001-06-07
IS2135B (is) 2006-08-15
SK287228B6 (sk) 2010-03-08
GB0214845D0 (en) 2002-08-07
KR20020058051A (ko) 2002-07-12
GB9928578D0 (en) 2000-02-02
NO322119B1 (no) 2006-08-14
PL357597A1 (en) 2004-07-26
US6750237B1 (en) 2004-06-15
HUP0203597A3 (en) 2005-07-28
DE60019162D1 (de) 2005-05-04

Similar Documents

Publication Publication Date Title
NO20022525L (no) Farmasöytiske formuleringer inneholdende zolmitriptan
GB0005251D0 (en) Therapeutic compounds
TR199901417T2 (xx) Analjezik etkisi olan yeni bile�imler.
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
DK0907365T3 (da) Hidtil ukendt formulering
DE60124684D1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
SE9900961D0 (sv) Novel compounds
SE9802208D0 (sv) Novel compounds
NO20004419L (no) Ny anvendelse
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
NO20011217D0 (no) Doseringsform omfattende væskeformulering
ATE301999T1 (de) Racecadotril enthaltende trockene pulverformulierung
YU16399A (sh) ) UPOTREBA INHIBITOR H +, K+ - ATP- aze I FARMACEUTSKA FORMULACIJA ZA SIMULTANU, SEPARATNU ILI SEKVENCIJALNU UPOTREBU, KOJA SADRZI INHIBITOR H +, K+-ATP- aze I GLUKOKORTIKOID INHIBITOR H +, K+- ATP- aze
ATE360428T1 (de) Analgetisches arzneimittel
SE0001916D0 (sv) Novel formulation
SE9802209D0 (sv) Novel compounds
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
AR023452A1 (es) Utilizacion del osanetant para preparacion de medicamentos utiles en el tratamiento de los trastornos del humor
SE9604752D0 (sv) Formulation and use
ES2159479A1 (es) Nuevos indazoles como inhibidores de la ciclooxigenasa-ii
TR200000916T2 (tr) İkameli piperidin türevleri.

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GRUENENTHAL GMBH, DE

MK1K Patent expired